International Thymic Malignancy Interest Group

“Financial and government documents are available in the office”

“Annual meeting”

“Support of the Foundation for Thymic Cancer Research and joint program services”

“database collection, management, and analysis”

“With 147 active members from 21 countries, ITMIG continues to be the leading scientific organization dedicated to thymic malignancies. ITMIG Committees are the core of our society, and beyond our Annual Meeting, are working all along the year on research projects, patients- and physicians-oriented initiatives, and developing the infrastructures for novel initiatives. Participation is open to all ITMIG members, and we need your input, engagement, and leadership in all these activities. The ITMIG prospective database is being transferred to a REDCap format, which allows better self-updating, higher compatibility with other systems, and more opportunities for developing a central platform for projects. It is also compliant with recent regulation on data usage. Thanks to the TYME network, the infrastructure database is now ready. A comprehensive review of data elements to be collected was done, and new fields have been added, especially to prepare the next version of the TNM classification. In 2022 and 2023, we organized nine clinical-radiological-pathological meetings, i.e. multidisciplinary Tumor Boards, at which patient cases are presented. In order to improve the organization of the meetings, we appointed a Tumor Board chair in 2023, with Annemarie Shepherd assuming this position. Two cases presented at the Tumor Board were subsequently published in Mediastinum. ITMIG declared May as Thymic Malignancy Awareness Month (TMAM). To mark the occasion, several webinars for physicians and patients were held in May. Some were prepared in cooperation with other scientific societies (the European Society of Pathology, the Society of Thoracic Radiology, the American Radium Society) or patient support groups (ThymicUK, TUTOR). Majority of webinars were recorded and are now available on ITMIG YouTube channel. In addition, a patient information brochure available in 11 languages, numerous informational posts on Facebook and interviews with prominent ITMIG members were prepared and published on the Mediastinum website. The time and effort spent preparing We recently initiated a project on the pathologic and radiologic tumor response to neoadjuvant therapy in thymic carcinomas, thymomas, and thymic neuroendocrine neoplasms. Aims of the study are to assess radiologic and pathologic response to neoadjuvant therapy and to correlate response with outcome. As we are still in the early stages of the project, anyone is welcome to join the project. A workshop of participating pathologists is planned in the morning of October 7th 2024, the day after the Annual ITMIG meeting, at NYU organized by Dr. Andre Moreira. The working group is assembling a multidisciplinary survey on questions relevant to various subspecialties, specifically focusing on questions towards cooperation between subspecialties and on current state of management of patients with thymoma and thymic carcinoma, aspects that were not included in the survey published by ITMIG and led by Dr. Annemarie Shepard in 2017, PMID: 27876674. We are currently working on a primary mediastinal germ cell tumor (PMGCT) project. Because of the paucity of PMGCT studies are in general small and information is relatively sparse. Furthermore, there is currently no agreed upon staging for PMGCT. We study the morphologic and imaging features of PMGCT and will correlate those with outcome. In addition, we will correlate demographic features and surgical treatment with outcome of patients and collect molecular data. Ultimately, we would like to establish a staging system for PMGCT. Currently, we review the morphologic and immunophenotypic features of PMGCT by web meetings. October 4-6, 2023, the Annual Meeting of ITMIG (13th) was held in New York. After three years of virtual meetings, we finally met in person! The conference was well attended, with 167 participants from 16 countries. The conference program included educational and scientific sessions, Radiation Oncology Workshop, patient sessions and also Oral”